News for Xspray Pharma AB (publ) (0GHZ.L)

Published at

Jun 28, 2024 3:49 PM

by rttnews.com

mixed

mixed

Biotech Stocks Facing FDA Decision In July 2024

Swedish pharmaceutical company Orexo AB's nasal rescue medication OX124 is under FDA review, with a decision anticipated on July 15, 2024..

0GHZ.L ZEG.DE PHAT AZNN.MX AZNCF AZN.L AZN ARQT ACOGF ACOG.V 0A4J.L

Read more →
Published at

Feb 23, 2023 8:02 AM

by prnewswire.com

positive

positive

Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (A

/PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the...

0GHZ.L

Read more →